Upadacitinib

Category: Arthritis



Upadacitinib Overview

Upadacitinib (trade name Rinvoq; code name ABT-494) is a drug for treatment of rheumatoid arthritis. Approved by U.S FDA on 16 August 2019.[2] It was developed by the biotech company AbbVie. Contents 1 Mechanism of action 2 Clinical trials 2.1 Phase I studies 2.2 Phase II studies 2.2.1 BALANCE I 2.2.2 BALANCE II 2.2.3 CELEST 2.3 Phase III studies 3 See also 4 References Mechanism of action The Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases who...

Read more Upadacitinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Upadacitinib

Recent Upadacitinib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Upadacitinib
  • Tablet, Extended Release: 15mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Upadacitinib or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 11 December 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA